Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4591064
Max Phase: Preclinical
Molecular Formula: C53H84N2O13S
Molecular Weight: 989.32
Molecule Type: Unknown
Associated Items:
ID: ALA4591064
Max Phase: Preclinical
Molecular Formula: C53H84N2O13S
Molecular Weight: 989.32
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@H](N3CCCS3(=O)=O)C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)CC[C@H]1O
Standard InChI: InChI=1S/C53H84N2O13S/c1-33-16-11-10-12-17-35(3)43(55-26-15-27-69(55,63)64)32-41-22-20-39(7)53(62,68-41)50(59)51(60)54-25-14-13-18-42(54)52(61)67-45(36(4)30-40-21-23-44(56)46(31-40)65-8)24-19-34(2)29-38(6)48(58)49(66-9)47(57)37(5)28-33/h10-12,16-17,29,33-34,36-37,39-46,48-49,56,58,62H,13-15,18-28,30-32H2,1-9H3/b12-10+,16-11+,35-17+,38-29+/t33-,34+,36-,37-,39-,40+,41+,42+,43-,44-,45+,46-,48-,49+,53-/m1/s1
Standard InChI Key: RUITWCMYAHZULA-IGGDOHASSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 989.32 | Molecular Weight (Monoisotopic): 988.5694 | AlogP: 6.39 | #Rotatable Bonds: 6 |
Polar Surface Area: 206.51 | Molecular Species: NEUTRAL | HBA: 13 | HBD: 3 |
#RO5 Violations: 3 | HBA (Lipinski): 15 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 9.96 | CX Basic pKa: | CX LogP: 7.05 | CX LogD: 7.05 |
Aromatic Rings: 0 | Heavy Atoms: 69 | QED Weighted: 0.15 | Np Likeness Score: 1.53 |
1. Abdel-Magid AF.. (2019) Rapalogs Potential as Practical Alternatives to Rapamycin., 10 (6): [PMID:31223435] [10.1021/acsmedchemlett.9b00215] |
Source(1):